@article{5d3bc8010248488ea878a606bea970eb,
title = "Measuring headache day severity using multiple features in daily diary designs",
abstract = "Objective: Though migraine is thought of as a symptom complex, symptoms are typically assessed one at a time. For use in clinical research, we developed a composite measure of headache day severity by combining eight well-known symptoms captured in daily diaries. Subjects and Methods: Data came from adults with a self-reported diagnosis of migraine (n = 4380) who provided daily diary information assessed using a novel digital platform. Nine observed features theoretically linked to headache day severity were analyzed using latent variable modeling to create a psychometrically robust headache day severity score. Logistic regression was used to assess the cross-sectional relationships of headache day severity scores against an array of clinically-relevant outcomes. Results: Participants were largely females (90%), approaching middle age (mean age of 37.3) and living in the United States (49%) or United Kingdom (23%). Findings supported a single latent headache day severity construct based on eight observed headache features. Headache day severity scores were associated with an increased odds of physician visits (Odds ratio[95% CI]: 1.71[1.32–2.21]), emergency department visits (4.12[2.23-7.60]), missed school/work (2.90[2.56–3.29]), missed household work (3.37[3.06–3.72]), and missed other activities (3.29[2.97–3.64]) (p <.0001 for all). Conclusions: Modern measurement techniques support a single headache day severity construct that reflects migraine is a symptom complex. The headache day severity scores were associated with external validators and initial visualizations showed how headache day severity scores can be applied broadly in clinical practice and research.",
keywords = "Headache severity, headache diaries, measurement",
author = "McGinley, {James S.} and Houts, {Carrie R.} and Wirth, {R. J.} and Lipton, {Richard B.}",
note = "Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Amgen, Inc. through the Competitive Grant Program in Migraine Research, which is an independently-reviewed competitive grant program supported by Amgen to fund innovative research advancing the medical knowledge of migraine. The sponsor did not interact with the authors regarding any aspect of the design, analysis, or interpretation of this study. The authors made the final decision to submit the manuscript for publication. Funding Information: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JS McGinley has received funding, research support, salary, or other compensation from Vector Psychometric Group LLC (Employment), Amgen, Inc. (Research Support), Cephalalgia (Biostatistics Editor), and the National Headache Foundation (Research Support). Carrie R Houts has received salary from Vector Psychometric Group, LLC (Employment). RJ Wirth has received salary or other compensation from Vector Psychometric Group, LLC (Management Position) and Cephalalgia (Biostatistics Editor). RB Lipton holds stock options in Biohaven Holdings and CtrlM Health. He serves as consultant, advisory board member, has received honoraria from or research support from: Abbvie (Allergan), American Academy of Neurology, American Headache Society, Amgen, Biohaven, Biovision, Boston, Dr Reddy{\textquoteright}s (Promius), Electrocore, Eli Lilly, eNeura, Equinox, GlaxoSmithKline, Grifols, Lundbeck (Alder), Merck, Pernix, Pfizer, Teva, Vector and Vedanta. He receives research support from the NIH and the FDA. Publisher Copyright: {\textcopyright} International Headache Society 2021.",
year = "2022",
month = jan,
doi = "10.1177/03331024211033829",
language = "English (US)",
volume = "42",
pages = "53--62",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "1",
}